← All trials
NCT05989542
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 29, 2023
- Primary completion
- Sep 30, 2026
- Completion date
- Sep 30, 2027
- First posted
- Aug 14, 2023
- Last posted
- Aug 18, 2023
- Enrollment
- 131
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Pearl Biotechnology Limited Liability CompanyLead sponsor
- Shantou UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.